Editorials

Extended Role Practitioners to Improve Access to Rheumatic Care: What is the Evidence in the Classification of Patients with Spondyloarthritis?
V. Lowry, F. Desmeules ............................................ 483

The “Renocentric Theory” of Renal Resistive Index: Is it Time for a Copernican Revolution?
G. Geraci, A. Sorce, G. Mulè .......................... 486

Scratching the Surface: Itching for Evidence to Reduce Surgical Health Disparities in Total Shoulder Arthroplasty
S.H. Liu, K.L. Lapane .......................... 490

Rheumatoid Arthritis

Longterm Drug Survival of TNF Inhibitors in Patients with RA
P. Emery, B. Vlahos, P. Szczypa, et al ......................................................... 493


Toward Defining Primary and Secondary Nonresponse in RA Patients Treated with Anti-TNF: Results from the BioTRAC and OBRI Registries

Rituximab Therapy for Systemic Rheumatoid Vasculitis: Indications, Outcomes, and Adverse Events
C.M. Coffey, M.D. Richter, C.S. Crowson, et al .................. 518

Spondyloarthritis

Advancing Early Identification of axSpA: An Interobserver Comparison of Extended Role Practitioners and Rheumatologists

Diffuse Idiopathic Skeletal Hyperostosis in Smokers and Restrictive Spirometry Pattern: An Analysis of the COPDGene Cohort
S.F. Oudkerk, F.A. Mohamed Hoesein, F.C. Öner, et al .................. 531

Psoriatic Arthritis

Secukinumab Immunogenicity over 52 Weeks in Patients with PsA and AS

Relationship Between Fatigue and Inflammation, Disease Duration, and Chronic Pain in PsA: An Observational DANBOY Registry Study

Systemic Lupus Erythematosus

Retinal Complications in Patients with SLE Treated with Antimalarial Drugs

Altered Homeostasis of Regulatory T Lymphocytes and Differential Regulation of STAT1/STAT5 in CD4+ T Lymphocytes in Childhood-onset SLE
M. Holcar, A. Goropevšek, T. Avčin .......................... 557

Systemic Sclerosis

Renal Parenchymal Thickness in Patients with SSc Is Related to Intrarenal Hemodynamic Variables and Raynaud Renal Phenomenon
A. Gigante, B. Barbano, M.L. Gasperini, V. Zingaretti, R. Cianci, E. Rosato ..................... 567

Vasculitis

The Longitudinal Course of Fatigue in ANCA–associated Vasculitis
L. O’Malley, K.L. Druce, D. Chanouzas, et al ..................... 572

Effect of Treatment on Damage and Hospitalization in Elderly Patients with Microscopic Polyangiitis and Granulomatosis with Polyangiitis

Osteoarthritis

Insurance Payer Type and Patient Income Are Associated with Outcomes after Total Shoulder Arthroplasty
J.A. Singh, J.D. Cleveland ................................. 589

Contents continued on page xii
<table>
<thead>
<tr>
<th>Title</th>
<th>Authors</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Effect of OA on Work Participation and Loss of Working Life–years</td>
<td>T. Kontio, E. Viikari-Juntura, S. Solovieva</td>
<td>597</td>
</tr>
<tr>
<td>Gout</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dissociation Between Clinical Benefit and Persistent Urate Lowering in Patients with Chronic Refractory Gout Treated with Pegloticase</td>
<td>M.H. Pillinger, T.R. Fields, A.E. Yeo, P.E. Lipsky</td>
<td>605</td>
</tr>
<tr>
<td>Changes in the Presentation of Incident Gout and the Risk of Subsequent Flares: A Population-based Study over 20 Years</td>
<td>M.M. Elfishawi, N. Zleik, Z. Kvrgic, et al.</td>
<td>613</td>
</tr>
<tr>
<td>Rising Incidence of Acute Hospital Admissions due to Gout</td>
<td>M.D. Russell, M. Yates, K. Bechman, et al</td>
<td>619</td>
</tr>
<tr>
<td>Fibromyalgia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>The Relation of Physical Comorbidity and Multimorbidity to FM, Widespread Pain, and FM-related Variables</td>
<td>F. Wolfe, J. Ablin, E.K. Guymer, G.O. Littlejohn, J.J. Rasker</td>
<td>624</td>
</tr>
<tr>
<td>Images in Rheumatology</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HCQ-induced Retinal Toxicity</td>
<td>K.L. Carter, D.V. Do</td>
<td>632</td>
</tr>
<tr>
<td>Letters</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Spinal Research — A Field In Need of Standardization</td>
<td>D.Z. Khan, B.M. Davies, M.R. Kotter</td>
<td>633</td>
</tr>
<tr>
<td>Discontinuation of Canakinumab following Clinical Disease Remission Is Feasible in Patients with Systemic JIA</td>
<td>D.N. Maritsi, O. Vougiouka, D. Eleftheriou</td>
<td>634</td>
</tr>
<tr>
<td>Is There a Role for LAMP-2 Autoantibodies in Patients with ANCA–associated Vasculitis?</td>
<td>S. Moiseev, A. Zykova, N. Bulanov, et al</td>
<td>636</td>
</tr>
<tr>
<td>Meetings</td>
<td></td>
<td>x</td>
</tr>
</tbody>
</table>